Concurrent Chemoradiotherapy with Cisplatin and Docetaxel for Head and Neck Squamous Cell Carcinoma

xlomafota13 shared this article with you from Inoreader Concurrent Chemoradiotherapy with Cisplatin and Docetaxel for Head and Neck Squamous Cell Carcinoma Via Clinical Otolaryngology Abstract Objectives Concurrent chemoradiotherapy (CCRT) with high-dose cisplatin is considered as the global standard therapy to treat patients with advanced head and neck cancer (HNSCC). High doses of cisplatin (100mg/m2) induce severe adverse effects that hinder the completion of therapy, and late toxicity, including renal dysfunction, may prevent patients from receiving treatment with second-line chemotherapies. Design We retrospectively analyzed the effect of CCRT combined with moderate-dose cisplatin (4x15 mg/m2) and docetaxel (50 mg/m2) in 83 patients with locally advanced HNSCC. Results The median follow-up period was 31 months (range 3-100 months). Radiotherapy was completed in 98% of patients including 36 patients (43%) aged 70 or older. The overall complete response rate was 87% with preserving renal function. The 3-year overall survival, disease-specific survival and progression-free survival rates were 71%, 81% and 70%, respectively. The 3-year disease-specific survival with organ preservation was 79%. Conclusion CCRT with a combination of moderate-dose cisplatin and docetaxel in HNSCC patients was well tolerated; it also demonstrated comparable clinical responses to CCRT using high-dose cisplatin View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.